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Abstract
Hypoxia is a critical driver of cancer pathogenesis, directly inducing malignant phenotypes such as epithelial-
mesenchymal transition, stem cell-like characteristics and metabolic transformation. However, hypoxia-associated pheno-
types are often observed in cancer in the absence of hypoxia, a phenotype known as pseudohypoxia, which is very well
documented in specific tumour types, including in paraganglioma/pheochromocytoma (PPGL). Approximately 40% of the
PPGL tumours carry a germ line mutation in one of a number of susceptibility genes of which those that are found in
succinate dehydrogenase (SDH) or in von Hippel-Lindau (VHL) genes manifest a strong pseudohypoxic phenotype.
Mutations in SDH are oncogenic, forming tumours in a select subset of tissues, but the cause for this remains elusive.
Although elevated succinate levels lead to increase in hypoxia-like signalling, there are other phenotypes that are being
increasingly recognised in SDH-mutated PPGL, such as DNA hypermethylation. Further, recently unveiled changes in
metabolic re-wiring of SDH-deficient cells might help to decipher cancer related roles of SDH in the future. In this review,
we will discuss the various implications that the malfunctioning SDH can have and its impact on cancer development.
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Introduction
In 2000, Hanahan andWeinberg introduced the concept of six
universal hallmarks of cancer (Hanahan and Weinberg 2000),
which were enhanced around 10 years later with a further two
hallmarks, and two ‘enabling characteristics’ (Hanahan and
Weinberg 2011). The hallmarks can be elicited as a result of
mutations in oncogenes and tumour suppressor genes—in-
deed, this is what the focus of much research has been on to
date. Interestingly, it has also been argued that most of the
hallmarks can arise as a result of the metabolic microenviron-
ment of the tumour and, in particular, the pervasive low oxy-
gen (hypoxic) environment often observed in most solid tu-
mours (Kroemer and Pouyssegur 2008; Wigerup et al. 2016).
Hypoxia is a critical driver of cancer pathogenesis, directly
inducing malignant phenotypes such as epithelial-
mesenchymal transition, stem cell-like characteristics, and
metabolic transformation. However, these hypoxia-driven
phenotypes are often observed in cancer in the absence of
hypoxia—a phenotype known as pseudohypoxia. This term
was originally coined in the early 90s, referring to hypoxia-
like change in the metabolic phenotype of cells in diabetes
(Williamson et al. 1993). Since then, the acquisition of
pseudohypoxic phenotypes has been observed in a number
of pathological and physiological processes, including inflam-
mation (Halligan et al. 2016), differentiation (Mohlin et al.
2017) and aging (Verdin 2015). The role of pseudohypoxia
in tumourigenesis is well documented in specific tumour
types, including in paraganglioma/pheochromocytoma
(PPGL). In this review, we first briefly describe the PPGL
tumours and general hypoxic signalling. Later, we focus on
hypoxia/pseudohypoxia, various pathways leading to this
condition and their relevance in the PPGL syndrome.
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Paraganglioma and pheochromocytoma
tumours
PPGL are tumours of neuroendocrine origin and can arise at
various sites of the body either of parasympathetic or sympa-
thetic lineage-derived cells. Approximately 40% of the PPGL
tumours carry a germ line mutation in one of a number of
susceptibility genes, which makes PPGL the cancer syndrome
with the highest reported degree of heritability (Dahia 2014).
More recently, apparently sporadic cases were shown to har-
bour somatic mutations in known susceptibility genes (and
some newly defined genes) which raises the number of a ge-
netic driver event in these cancers to up to 70–80%
(Burnichon et al. 2016; Curras-Freixes et al. 2017).
Seventeen years ago, the first germ line mutation associat-
ed with this disease was identified in the SDHD gene, which
encodes for one of four subunits of the enzyme, succinate
dehydrogenase enzyme (SDH), also known as mitochondrial
complex II (CII) (Baysal et al. 2000) (Fig. 1a). This was a
significant finding, as until that date, no direct connection
between the metabolic dysfunction and the causation of can-
cer had been identified. This finding also contributed to the
renewed interest in OttoWarburg’s postulate almost 100 years
before that defective mitochondrial metabolism was the major
cause of cancer development (Koppenol et al. 2011). Over the
next few years, mutations in the other three SDH genes (A, B
and C) and its assembly factor (SDHAF2) were also observed,
adding considerable evidential weight to SDHx genes being
critical tumour suppressors linked to PPGL (Astuti et al. 2001;
Burnichon et al. 2010; Hao et al. 2009; Niemann and Muller
2000). Subsequently, mutations in other genes encoding met-
abolic enzymes with a role in the tricarboxylic acid cycle
(TCA) followed; fumarate hydratase (FH) (Castro-Vega
et al. 2014; Letouze et al. 2013) and malate dehydrogenase
(MDH2) (Cascon et al. 2015) (Fig. 1b). However, it is not
only genes encoding metabolic enzymes that are associated
with PPGL. Long before the discovery of mutations in SDHx
in PPGL, the major genetic mutations associated with these
cancers were of neurofibromatosis-1 (NF1), RET and von
Hippel-Lindau (VHL) (Else 2015). Interestingly, the transcrip-
tional profiling of tumours with mutations in these different
genes shows that they segregate into two clusters: a
‘pseudohypoxic’ cluster that includes tumours with VHL and
SDHx mutations and an ‘activated tyrosine kinase’ cluster,
originally containing tumours with RET and NF1(Dahia
et al. 2005). More recently, further clustering analyses have
Fig. 1 SDH structure and its role in TCA cycle. aAssembly of four SDH
subunits (SDHA-D) into functional SDH and its position in the
mitochondrial inner membrane (IMM) facing matrix. The catalytic
subunit SDHA contains the flavin cofactor FAD which accepts
electrons from succinate and passes them to FeS centres in the SDHB
subunit. The electrons are then accepted by membrane carrier ubiquinone
(Q) at the Q binding site comprised by membrane embedded SDHC and
SDHD subunits. Reduced Q (QH2) transfers electrons within the IMM to
complex III. b Enzymes of TCA cycle and accompanying replenishing
reactions. CS citrate synthase, IDH isocitrate dehydrogenase, OGHD
oxoglutarate dehydrogenase, SDH succinate dehydrogenase, FH
fumarate hydratase, MDH malate dehydrogenase, PDH pyruvate
dehydrogenase, PC pyruvate carboxylase, GOT glutamate-oxaloacetate
transaminase, GLDH glutamate dehydrogenase. Enzymes with mutations
found in PPGL are outlined in orange. Grey colour depicts pathways
important in SDH deficiency (see text for details)
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been performed that have highlighted new subgroups
(Fishbein et al. 2017), but the pseudohypoxic grouping based
around SDH and VHL mutations remains a major phenotyp-
ically characterised cluster.
Metabolic alterations in cells with mutations
in TCA cycle enzymes
Since cancer is characterised by an unrestricted growth, it
seems counterproductive that deficiencies in apparently es-
sential metabolic enzymes can be oncogenic. However, stud-
ies into the metabolic alterations in cells harbouring mutations
in TCA cycle enzymes have been held back by the lack of
appropriate cell models. Indeed, investigations that have
utilised cells with varying degrees of knockdown have
yielded conflicting results; most likely due to insufficient
knockdown, or perhaps different cell backgrounds. More re-
cently, novel models of FH and SDHx deficiency have been
created using the Cre-lox system and have provided important
information regarding the re-wiring of the metabolic network
in response to loss of these key enzymes (Cardaci et al. 2015;
Frezza et al. 2011; Lussey-Lepoutre et al. 2015). The fact that
the TCA cycle is actually not a true cycle, but that its metab-
olites are replenished or used up by various other intercon-
nected pathways, very probably is the key to cell survival in
the absence of these enzymes. However, it remains a critical
unanswered question as to why these tumours only arise in
certain cell types—suggesting that some of the metabolic re-
wiring required for survival is inconsistent with viability in
most differentiated cell types.
The mechanism of survival of FH-deficient cells was orig-
inally elucidated by Frezza and colleagues using Fh1-defi-
cient epithelial kidney cell lines in 2011 and showed that
the haem biosynthetic pathway became essential in these con-
ditions (Frezza et al. 2011). They found that the TCA cycle
truncation at FH led to an accumulation of mainly glutamine-
derived fumarate (and to some degree, succinate), but low
malate and citrate levels. Interestingly, although mitochondri-
al respiration was decreased, Fh1-deficient cells still retained
normal mitochondrial membrane potential and were capable
of generating and oxidising NADH. This NADH was very
probably produced by glutamate metabolism through gluta-
mate and 2-oxoglutarate (2OG) dehydrogenases (see Fig. 1b
brown dashed lines). However, this critical metabolic activity
could only be maintained through a metabolic ‘escape
route’—the haem biosynthesis pathway. This pathway, which
was found to be essential in FH-deficient cells, metabolises
succinyl-CoA to synthesise haem, but in this case, further
metabolises the haem to form bilirubin, which is excreted
(Frezza et al. 2011). Further, metabolic re-wiring was ob-
served in these cells that impinged on urea cycle activity
(Adam et al. 2013; Zheng et al. 2013). FH-deficient cells have
been shown to metabolise fumarate through reversal of the
activity of argininosuccinate lyase, using arginine and accu-
mulated fumarate to produce argininosuccinate, which they
also excrete (Adam et al. 2013; Zheng et al. 2013).
Two recent studies on metabolic re-wiring in SDH-
deficient cells have shown that a seemingly similar metabolic
deficiency results in an significantly different metabolic phe-
notype, with cells dependent on pyruvate carboxylase (PC)
activity for aspartate synthesis (Cardaci et al. 2015; Lussey-
Lepoutre et al. 2015) (see Fig. 1b grey dashed lines).
Additionally, it was observed that SDH-deficient cells exhibit
perturbed redox homeostasis—evidenced by increased pyru-
vate reduction to lactate (Cardaci et al. 2015). This is likely a
consequence of altered TCA cycle activity, but the precise
nature of the change in redox function within SDH-deficient
cells is still unclear, with a further study suggesting that SDHx
mutations that are oncogenic differ from those associated with
neurodegenerative diseases in that only the former result in
decreased NADH oxidation by complex I of the respiratory
chain (Lorendeau et al. 2017). It is interesting that neither
Cardaci et al. nor Lussey-Lepoutre et al. presented data re-
garding whether deficiencies in SDH lead to an increase in
the haem biosynthesis pathway, reminiscent of FH-deficient
cells (Cardaci et al. 2015; Lussey-Lepoutre et al. 2015).
Clearly, this is an attractive hypothesis, and the lack of data
presented suggests that the results from their studies were not
as clear-cut as expected. It appears therefore that our under-
standing of the metabolic consequences of apparent loss of
function mutations within the subunits of SDH remains very
much incomplete, and further studies are warranted.
Metabolic signalling in pseudohypoxic
systems
In addition to the metabolic re-wiring that occurs as a conse-
quence of loss of function of TCA cycle enzymes, the metab-
olites that accumulate have also been shown to act as signalling
molecules, directly inducing malignant phenotypes. Many
TCA cycle metabolites can serve as a signal influencing various
cellular processes (Frezza 2017), but 2OG, succinate and fuma-
rate stand out when it comes to hypoxic and pseudohypoxic
signalling with a profound impact on cancer evolution and
progression (Morin et al. 2014; Sullivan et al. 2016).
One of the most important longer-term physiological re-
sponses to hypoxia is the increase in red blood cell production
to aid oxygen delivery to peripheral tissues (Weir et al. 2005).
The mechanism by which this occurs was first described in
1992, involving hypoxia-induced binding of the transcription
factor, hypoxia-inducible factor 1 (HIF1), to the promoter of
the erythropoietin gene (Semenza andWang 1992). In the same
year, vascular endothelial growth factor (VEGF) was shown to
mediate hypoxia-induced angiogenesis (Plate et al. 1992;
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Shweiki et al. 1992) and was subsequently also confirmed as a
HIF1 target gene (Forsythe et al. 1996). Since then, HIF1 has
been shown to regulate the expression of hundreds of genes,
including those encoding for metabolic enzymes (e.g. lactate
dehydrogenase A and pyruvate dehydrogenase kinase 1), an-
giogenic factors, extracellular matrix remodelling enzymes and
cell cycle regulating factors (Pugh and Ratcliffe 2017).
The hypoxia-inducible factor (HIF) transcriptional factors
are formed of two constitutively expressed subunits—alpha
and beta (the latter originally named the aryl hydrocarbon re-
ceptor nuclear translocator (ARNT)) (Wood et al. 1996).
Oxygen sensitivity is achieved through the rapid post-
translational modification and degradation of the α subunit in
normoxia, which means that in these conditions, no active HIF
heterodimer can be formed (Fig. 2). There are threeα subunits,
two of which form active transcription factors, known as HIF1
and HIF2 (HIF2α originally known as endothelial PAS
domain protein 1) (Tian et al. 1997). The function of both
factors is regulated by the action of three oxygen-dependent
prolyl 4-hydrogenase (PHDs1-3) that hydroxylate HIFα sub-
units on specific prolyl residues, thereby forming a recognition
site for the von Hippel-Lindau (pVHL)-containing E3 ligase
complex, which binds and induces the polyubiquitylation of
the HIFα subunits, leading to their proteasomal degradation.
Loss of pVHL expression in some PPGL therefore elicits a
pseudohypoxic phenotype through the inappropriate
stabilisation of HIFα subunits in normoxia. The hydroxylation
reaction performed by the PHD enzymes requires oxygen and
a metabolic intermediate—2-oxoglutarate—as substrates, as
well as ferrous iron and ascorbate as cofactors (Ploumakis
and Coleman 2015). Of the three PHD enzymes that are
known to hydroxylate the HIFα subunits, PHD2 is thought
to be the major regulator of HIF1α expression, while PHD1
and 3may have a preference for HIF2α (Bruick andMcKnight
Fig. 2 HIF degradation pathway in normoxia and its stabilisation in
hypoxia and pseudohypoxia. Under normoxic oxygen levels, PHD
enzymes hydroxylate HIFα subunit on specific proline residues. These
are recognised by VHL ubiquitin ligase which targets HIFα for
proteasomal degradation (first panel). Under conditions of low oxygen
levels, PHD enzymes are inhibited and HIFα protein is stabilised, binds
HIFβ subunit and transactivates HIF responsive genes (middle panel). In
pseudohypoxic conditions depicted here by SDH deficiency, high
succinate levels restrict the PHD reaction by product inhibition and
HIFα is stabilised under conditions of normoxic oxygen levels (last
panel)
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2001; Ivan and Kaelin Jr. 2017; Taniguchi et al. 2013).
Additionally, the PHDs are thought to have non-HIF targets,
with PHD3 playing a role in regulation of apoptosis (Lee et al.
2005; Tennant and Gottlieb 2010) and metabolism (German
et al. 2016; Luo et al. 2011). Although the PHD enzymes
control HIFα stabilisation, a further level of oxygen and
2OG-mediated control is provided by factor inhibiting HIF
(FIH), which hydroxylates HIFα on an asparaginyl residue
in the C-terminal transactivation domain (CAD) abrogating
its interaction with p300, thereby preventing transcriptional
activation (Hewitson et al. 2002).
PHD and FIH enzymes that target HIFα subunits are not the
only 2OG-dependent dioxygenases but belong to a large fam-
ily of more than 70 enzymes (Ploumakis and Coleman 2015).
These include important demethylases that modulate the epi-
genome and in this way can affect multiple cellular pathways
and play a prominent role, particularly in cancer. Recently, it
was shown that ten-eleven translocation (TET) DNA hydrox-
ylases, which demethylate genomic DNA in a multistep pro-
cess initiated by hydroxylation of 5-methylcytosine, manifest
reduced activity by tumour hypoxia in human and mouse cells
and result in hypermethylation of the tumour suppressor gene
promoters. Interestingly, the authors provide evidence that this
change in TET activity depends directly on availability of ox-
ygen (Thienpont et al. 2016).
The first association of increased concentrations of metab-
olites and the pseudohypoxic phenotype was revealed in 2005
when the link was provided between loss of SDH function,
increased succinate levels and the resulting inhibition of 2OG-
dependent PHD enzymes and stabilisation of HIFα subunits
under normoxic conditions (Selak et al. 2005). Increased levels
of succinate in tumour samples from PPGL patients have been
confirmed in a number of studies (Imperiale et al. 2015;
Lehtonen et al. 2007; Lendvai et al. 2014; Pollard et al.
2005; Richter et al. 2014) and high succinate to fumarate ratios
suggested as a metabolic marker for the detection of SDHB/
SDHD-related PPGL tumours (Lendvai et al. 2014). As the
hydroxylation of HIFα by PHDs oxidatively decarboxylates
2OG to form succinate (Ploumakis and Coleman 2015), at
least some of the effect of succinate is likely through product
inhibition of the PHDs (see Fig. 2). Similarly to high succinate
levels, fumarate has also been shown to inhibit PHDs and
stabilise HIFα when FH was inactivated (Isaacs et al. 2005).
In contrast to PHDs, the other HIFα-acting hydroxylase, FIH
(factor inhibiting HIF), appears relatively insensitive to inhibi-
tion by succinate or fumarate accumulation (Koivunen et al.
2007). The effect of another more recently described 2OG-like
metabolite, 2-hydroxyglutarate (2-HG), which arises as the
result of oncogenic isocitrate dehydrogenase (IDH) mutations,
is not yet clear, seemingly dependent on the 2OG-dioxygenase
enzyme involved. D-2-HG can increase or decrease the activ-
ity of PHDs, while the L-2-HG has been reported to compet-
itively inhibit PHD enzymes (Sullivan et al. 2016), although
this may be through non-enzymatic oxidation to 2OG
(Tarhonskaya et al. 2014). Recently, other means of inhibiting
PHD enzymes have been suggested, including deficiencies in
the TCA cycle enzyme, 2OG dehydrogenase (Burr et al. 2016)
and depletion of intracellular cysteine (Briggs et al. 2016).
With respect to non-HIF-mediated mechanisms of
pseudohypoxia, it was recently shown that fumarate accumu-
lation can drive a number of additional HIF-independent phe-
notypes, including TANK-binding kinase 1 (TBK1)-mediated
activation of nuclear factor kappa-light-chain-enhancer of ac-
tivated B cell (NFκB) signalling (Shanmugasundaram et al.
2014) and succination of an steadily increasing number of
proteins (Blatnik et al. 2008; Kinch et al. 2011; Miglio et al.
2016; Ternette et al. 2013; Yang et al. 2014).
Interestingly, the pseudohypoxic cluster of PPGL associat-
ed with SDHx and VHL mutations can be further stratified
using the DNA methylation profile (Letouze et al. 2013).
The ‘hypermethylator’ phenotype of SDHx-mutated tumours
is a product of succinate-dependent inhibition of the TET
family of DNA demethylases (Killian et al. 2013; Kiss et al.
2008; Letouze et al. 2013; Xiao et al. 2012), hence is not
observed in VHL-mutated disease. Interestingly, tumours
harbouring mutations in FH were also found to have
hypermethylated DNA similarly to the SDHB tumours, in
which the epigenetic silencing was particularly severe com-
pared to those tumours with mutations in other SDH subunits
(Castro-Vega et al. 2014; Letouze et al. 2013). It was proposed
that SDH inactivation may be more complete in SDHB-
mutated tumours vs. tumours with mutations in other SDH
subunits resulting in a stronger inhibition of 2-OG-
dependent demethylation due to higher succinate levels, but
the authors were unable to confirm this hypothesis experimen-
tally (Letouze et al. 2013).
HIF association with cancer and PPGL
As already mentioned in the ‘Introduction’, there are a number
of means by which HIF signalling is beneficial for tumours.
However, although HIF1 and HIF2 share many common fea-
tures, the timing and regulation of their stabilisation and dif-
ferences in the genes they control mean that their relative
expression, which could be influenced by factors including
oxygen tension and cellular metabolism, will significantly in-
fluence the final hypoxic phenotype (Keith et al. 2011). This is
also likely true of pseudohypoxia. Although HIF1α is ubiqui-
tously expressed, HIF2α was first thought to be endothelial
cell specific. However, it has now been confirmed in non-
endothelial cells of various tissues, including brain, heart,
lung, kidney, liver, pancreas and intestine (Wiesener et al.
2003). Further complexity lies within the nature of the genes
whose expression is altered by the different HIF transcription
factors. An example of this is that HIF1 activity increases
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expression of enzymes that control glucose metabolism, while
HIF2 can drive de-differentiation through increasing expres-
sion of proteins such as SOX2, NANOG and OCT4—well-
described stem cell markers (Covello et al. 2006; Lee et al.
2016b). A final way in which the HIF transcription factors
may produce divergent phenotypes is through their interaction
with and control by other cancer-associated factors, such as
p53, mTOR andMYC (Keith et al. 2011). In contrast to HIF1,
HIF2 has been suggested to inhibit p53 and stimulate
mTORC1 to promote proliferation in hypoxia. HIF1 also is
thought to disrupt MYC-dependent gene transactivation,
while HIF2 collaborates with MYC to promote its oncogenic
activities (Keith et al. 2011).
Besides the benefits of neovascularisation driven by HIF-
dependent VEGF expression, HIF also orchestrates a metasta-
tic transcriptome, including downregulation of the intercellular
adhesion molecule E-cadherin (Esteban et al. 2006) and deg-
radation of extracellular matrix (Krishnamachary et al. 2003).
HIF1 also promotes genome instability through suppression of
DNA repair pathways and inhibition of DNA mismatch repair
gene (Bristow and Hill 2008). Both HIF1 and HIF2 induce
chemoresistance by increasing expression of drug efflux
pumps from the ATP-binding cassette transporter family
(Comerford et al. 2002; Martin et al. 2008), and they are in-
volved in the hypoxia-induced resistance to radiotherapy
(Bertout et al. 2009; Harada et al. 2012). Importantly, the
HIF transcription factors are master regulators of a
(pseudo)hypoxia-induced metabolic reprogramming that in-
duces increased glucose metabolism (a Warburg phenotype,
when in pseudohypoxia), suppresses glucose oxidation in the
mitochondria and supports synthesis of various macromole-
cules and building blocks needed for constant DNA replication
and cellular growth (Vander Heiden et al. 2009).
In most tumours, hypoxia and pseudohypoxia may repre-
sent a consequence of cancer development and progression.
However, in the pseudohypoxic cluster of PPGL, the
pseudohypoxic phenotype is likely causal (Amorim-Pires
et al. 2016). Increased stabilisation of both HIF1 and 2 have
been reported in PPGL tissues (Favier et al. 2009; Lopez-
Jimenez et al. 2010; Pollard et al. 2005; Pollard et al. 2006),
but consistently with other pseudohypoxic tumours, the role
of HIF2 may be more important and widespread (Comino-
Mendez et al. 2013; Welander et al. 2014). Since the first
report of an EPAS1 (HIF2α) mutation in PPGL in 2012
(Zhuang et al. 2012), a number of studies have demonstrated
EPAS1 mutations, with an overall frequency suggested as be-
tween 6 and 12% (Toledo 2017).
Although VHL and SDHx-mutated PPGLs cluster together
on the basis of their pseudohypoxic phenotype (Dahia et al.
2005), differences in the precise nature of their pseudohypoxic
signature have been reported (Favier et al. 2009; Lopez-
Jimenez et al. 2010), with strong activation of HIF1 target
genes in VHL-mutated PPGL (Burnichon et al. 2016; Lopez-
Jimenez et al. 2010). A higher mRNA expression of the HIF1
(but not HIF2) target genes, GLUT1 and HK2, was reported in
VHL-mutated compared to SDHB-mutated adrenal medulla
tissue (Fliedner et al. 2012), and VHL-mutated tumours dem-
onstrate increased glycolysis in comparison to SDHx-derived
PPGL (Favier et al. 2009). Interestingly, though strong HIF2α
staining has been shown in both VHL-mutated and SDH-mu-
tated tumours (Favier et al. 2009; Lopez-Jimenez et al. 2010),
PPGL with HIFα mutations demonstrate a different
pseudohypoxic transcriptome, suggesting that a further tran-
scriptional driver is involved (Fliedner et al. 2016). Consistent
with this, there is evidence that activation of HIFs may be
important, but not sufficient, for the fully malignant pheno-
type of pseudohypoxic tumours. In a mouse HLRCC mode
with renal tubule-specific Fh1−/−, genetic inactivation of
HIF1α or HIF2α, either alone or in combination, failed to
ameliorate the development of renal cysts (Adam et al.
2011). Indeed, as the cystic phenotype was exacerbated in
the Fh1−/−/Hif1−/−model, it was suggested that in this system,
it may be tumour suppressive (Adam et al. 2011). Hence,
although the role of HIF2 as driving malignancy is clear, the
role of HIF1 is less so and may be instead supportive of on-
cogenic transformation.
The role of reactive oxygen species in hypoxia
and pseudohypoxia
Reactive oxygen species (ROS) are damaging molecules con-
taining oxygen with an unpaired (free) electron that are capa-
ble of oxidising cellular macromolecules (Lambert and Brand
2009). The reduction of molecular oxygen with a single elec-
tron forms superoxide, which is highly reactive, but with lim-
ited permeation through the cell. Superoxide can, however, be
reduced to form hydrogen peroxide, a less reactive ROS,
which may be able to travel further in the cell, damaging more
distant cellular components (Murphy 2009). This effect,
though, is off-set through the activity of cellular peroxiredoxin
enzymes, which are present at high levels both in the mito-
chondria and in the cytosol and represent an extremely effec-
tive means of detoxifying hydrogen peroxide (Cox et al.
2009). It is a distinct possibility that the localisation of the
mitochondria within cells—whether perinuclear or more pe-
ripheral—could influence the cellular components that are
damaged. A direct role for hydrogen peroxide is therefore
unclear. Although ROS are critical for normal cell function,
they are also responsible for the oxidative damage observed in
pathologies such as neurodegenerative diseases and cancer.
Indeed, the oxidative damage of DNA by ROS is thought to
be a significant driver of genome instability and therefore
mutational load in tumours (Jackson et al. 1998; Kruk and
Aboul-Enein 2017). Environments that increase ROS produc-
tion are therefore likely to be pro-tumourigenic—a hypothesis
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supported by studies of the effect of environmental oxygen on
tumour initiation (Sung et al. 2011). In most cell types, the
mitochondria are the major source of ROS, having at least 10
known sites capable of ROS generation, including the electron
transport chain (ETC) (Lambert and Brand 2009) of which
SDH is an integral part (Fig. 3a).
Though complexes I and III are considered the major ROS
producing sites in the ETC, recent studies have shown that
under certain circumstances, SDH can also produce a signifi-
cant amount of ROS (Kluckova et al. 2015; Quinlan et al.
2012) suggested to approach the levels produced by complex
III when the redox state of the ETC is suboptimal (Quinlan
et al. 2012). It is therefore important to note that excessive
ROS levels have been shown to stabilise HIFα regardless of
oxygen tension (Guzy et al. 2005), and it has been suggested
that this mechanism, through an intact ETC, may be involved
in hypoxia-mediated HIFα subunit stabilisation (Chandel
et al. 1998). Downregulation of ETC components by either
silencing a subunit of complex III or removing cytochrome c
has been shown to attenuate HIF1α stabilisation under hyp-
oxia, but retained the ability to stabilise HIF when challenged
with direct PHD enzyme inhibitors, such as iron chelators
(Brunelle et al. 2005; Guzy et al. 2005; Mansfield et al.
2005). Increased ROS production from the ETC has been
suggested to contribute to HIF stabilisation and induction of
pseudohypoxia in SDH-mutated PPGL (Guzy et al. 2008).
Considering the necessity of the ROS signal for HIF
stabilisation under normoxic or hypoxic conditions (Lee
et al. 2016a; Waypa et al. 2016), the possibility of increased
ROS signalling in SDH-derived tumours has to be considered.
However, the experimental evidence for increased ROS in
various models of SDH dysfunction is not consistent, with
evidence suggesting that they are increased (Guzy et al.
2008; Ishii et al. 2005; Saito et al. 2016) or normal (Cervera
et al. 2008; Selak et al. 2005). The authors in the mentioned
studies chose to genetically manipulate different SDH sub-
units of which all impaired SDH activity to various levels
(but none of which resulted in complete loss of activity, as
observed in patient tumours), and despite the disparate obser-
vations regarding ROS production, HIF stabilisation was ob-
served in all models whether higher ROSwere detected or not.
As mentioned previously, HIF stabilisation in SDH dysfunc-
tional cells is expected through non-ROS mechanisms, as in-
creased succinate levels are known to inhibit the PHD en-
zymes, and therefore, a thorough examination of the potential
role of ROS, independently of other factors, is still required. A
study by Guzy and colleagues reported increased ROS in cells
stably silenced for SDHB, and this ROS production was sup-
pressed by addition of the SDHA site inhibitor. While SDHB
knockdown induced ROS and stabilised HIF, SDHA knock-
down did not (Guzy et al. 2008). Further, the authors showed
that pharmacological inhibition of the ubiquinone-binding site
formed by SDHC/SDHD subunits resulted in ROS production
and HIF stabilisation. This study therefore provided experi-
mental proof for the production of ROS in PPGL arising from
SDHB-D mutations. It is possible that tumours founded upon
SDHA mutations, which were only characterised in 2010
(Burnichon et al. 2010), may be different in terms of their
ROS production. Contrary to Guzy’s observations of ROS
production after SDHB downregulation, Cervera et al. were
unable to detect measureable changes in ROS levels, and by
assessing this in cells silenced for SDHB either transiently,
Fig. 3 Electron transport chain
and reverse electron transfer. a
Membrane carrier ubiquinone
accepts electrons from CI and
SDH (QH2) and transports them
to CIII from where the electrons
are carried by cytochrome c (cyt
c) to CIV and reduce molecular
oxygen to water. b Under
conditions of high concentrations
of succinate and high
mitochondrial transmembrane
potential (ΔΨ), the ubiquinone
pool becomes over-reduced and
transfers electrons to CI where
they escape as ROS
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stably or by expression of missense mutant SDHB genes,
these authors were unable to support a hypothesis that alter-
ations in SDHB activity could result in increased ROS pro-
duction (Cervera et al. 2008). Interestingly, among other cell
models used, both studies used human hepatoma Hep3B cell
line but different ROS detection strategies. Also throughout
the other studies mentioned, various ROS detection tech-
niques were used and often more approaches to validate the
results obtained with one detection system, but within one
study, various detection methods yielded similar results, so it
is not easy to ascribe the inconsistency in ROS observations to
variability in the detection systems.
Important direct evidence for the interplay between succi-
nate and ROS production by mitochondria arose from the
studies of isolated mitochondria, which showed that high con-
centrations of succinate elicit very high ROS production (as
discussed in Lambert and Brand (2009)). These ROS were
found to be due to a reverse electron transfer (RET) from an
over-reduced ubiquinone pool which lies between complex I/
II and complex III within the ETC (Lambert and Brand 2009)
(Fig. 3b). This effect was confirmed in a physiologically rel-
evant model of cardiac or brain ischemia/reperfusion injury,
where RET is the result of hypoxic succinate accumulation in
affected tissues and high SDH activity occurred during subse-
quent reperfusion (Chouchani et al. 2014).
Important evidence for the role of mitochondrial regulation
in paragangliomas can be observed in the normal function of
the carotid body—a common site for these tumours to form. In
the glomus cells of this tissue, functional complex I of the
ETC was suggested as a necessary requirement for oxygen
sensing (Fernandez-Aguera et al. 2015) through the study of
complex I-deficient (Ndufs2−/−) mice. In these mice loss of
responsiveness to hypoxia was observed, which was sug-
gested to be due to loss of a required ROS signal from com-
plex I. Interestingly, the authors noted high SDH activity in
glomus cells in wild-type mice, which was accompanied by
high levels of succinate, suggestive of RET and ROS produc-
tion (Fernandez-Aguera et al. 2015). It is therefore highly
relevant in the SDH-deficient model as to the nature of SDH
inactivation, and whether complex I is inactivated as previ-
ously suggested (Lorendeau et al. 2017), as this may represent
a reason for not only some of the discrepancies in experimen-
tal findings about ROS production in these models, but also
the biological outcomes of loss of SDH function. In the con-
text of pheochromocytomas, if RET from high succinate via
complex II is involved in the oxygen sensing, SDH mutations
should impair the organismal hypoxia response and would be
expected to result in the abolition of catecholamine secretion
through loss of ROS-mediated K+ channel modulation.
However, the opposite is true—patients do not lose ability to
synthesise catecholamines (Zuber et al. 2011). Additional ev-
idence arises from studies of mice heterozygous for Sdhd,
which despite being haploinsufficient show persistent carotid
body glomus cell activation and full responsiveness to hypox-
ia which suggests that complex II is probably not directly
involved in carotid body oxygen sensing (Piruat et al. 2004).
Interestingly, no tumours were observed in these mice, nor in
those with catecholaminergic tissue-specific Sdhd−/− (Diaz-
Castro et al. 2012; Piruat et al. 2004).
Conclusions/summary
Mutations in SDH (and other TCA cycle enzymes) are onco-
genic, forming tumours in a select subset of tissues. The rea-
son for this tissue selectivity remains unknown—something
that is not helped by the fact that despite continued attempts,
mouse models driven by loss of these enzymes do not appear
to form tumours (Diaz-Castro et al. 2012; Lepoutre-Lussey
et al. 2016; Macias et al. 2014; Pollard et al. 2007; Rankin
et al. 2006). Although VHL-driven tumour models have been
achieved, this was possible by mutating further tumour sup-
pressor genes (Bailey et al. 2017; Harlander et al. 2017). It is
therefore probable that in common with this, additional muta-
tions are required in addition to those in SDH subunits to
reproduce the human disease in mice (Adam et al. 2014).
Consistent with this, mutations in the genes encoding ATRX
(involved in telomere maintenance) and in the promoter re-
gion of telomerase itself (TERT) have been reported in SDH-
deficient tumours (Fishbein et al. 2015; Papathomas et al.
2014). Interestingly, with the advent of next generation se-
quencing technologies, increasing numbers of metabolic en-
zymes are being suggested as drivers of PPGL (Castro-Vega
et al. 2014; Toledo et al. 2013). Although this introduces an
apparent increase in complexity to the field, it is likely that
these mutations will greatly help our understanding of the
metabolic changes required for transformation—whether this
is increased succinate concentrations, changes in redox ho-
meostasis, ROS production, the pseudohypoxic signalling
cascades observed or indeed more complex metabolic chang-
es. Indeed, it is even possible that increased succinate concen-
trations are not the oncogenic driver after all.
Given the range of mutations observed in PPGL represent-
ed by VHL, EGLN1 (PHD2) and EPAS1 (HIF2α) of which all
directly control hypoxic signalling and with SDH and FH
mutations further providing a link to hypoxia, pseudohypoxia
seems to be an undeniable feature of PPGL. Intriguingly,
pseudohypoxic HIF signalling has also been suggested as an
important driver in the tumourigenesis of tumours with muta-
tions observed in cluster 2 PPGL, as their signalling via Ras/
MAPK, PI3K/AKT and mTORC pathways could result in
increased HIF signalling (Jochmanova et al. 2013).
Increased activity of these pathways is very common in many
different cancer types and has been shown to upregulate HIF,
but this is yet to be demonstrated in cluster 2 PPGL, indeed,
the fact that they are cluster 2 is a de facto demonstration that
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they differ significantly from the pseudohypoxic cluster
(Dahia et al. 2005; Fishbein et al. 2017; Lopez-Jimenez
et al. 2010). Nevertheless, as the links between hypoxia and
HIF stabilisation in PPGL cancers are too strong, it remains
something to be considered—especially given the ongoing
clinical trials evaluating agents that target drivers and effectors
of the pseudohypoxic phenotype: the VEGFA receptor and
HIF2α (Toledo 2017). We are in a highly exciting time for
this rapidly evolving field, where novel technologies are
playing a vital role in revolutionising our understanding of
the biology of these tumours. The outlook for patients with
these tumours is therefore improving and will continue to do
so as new findings are translated into novel therapies.
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